Endometrial Cancer Trial, Recruiting NCT05282095 Sponsor: Fujian Maternity and Child Health Hospital Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT05282095
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman aged 18 to 45 years old who wishes to become pregnant
  • You have been diagnosed with a specific type of cervical cell change (called HSIL/CIN2 or CIN2-3) confirmed by a cervical tissue biopsy taken within the last 3 months
  • You have not yet had any surgery, physical treatment, or medication treatment for this cervical condition
  • The affected area on your cervix, as seen during a specialist examination (colposcopy) within the last 3 months, covers less than half of the total cervical surface
  • You and your doctor have agreed to monitor your condition over 12 months without treatment, unless it gets worse
  • You are willing to attend follow-up appointments for 12 months and sign a consent form to take part

Who may not be able to join:

  • Your cervix has a particular type of transformation zone (called Type III) as seen on a specialist examination within the last 3 months (confirm with trial site)
  • You are currently pregnant or breastfeeding
  • You have a history of cancer affecting the reproductive organs
  • You have previously had your womb (uterus) removed, had cervical surgery, or received radiation therapy to the pelvic area
  • You have had physical treatment to the cervix within the last 24 months
  • You currently have a serious active disease affecting your immune system
  • You have been regularly using contraceptive medication within the last 12 months
  • You have used vaginal medication or douching within the 72 hours before your sample is taken (you may be able to re-enroll 3 days after stopping)
  • You have had sexual intercourse within 24 hours before your sample is taken (you may be able to re-enroll 24 hours after stopping)
  • You have received treatment for a genital tract infection, HPV, or a sexually transmitted infection within the last month (you may be able to re-enroll one month after finishing treatment)
  • You have taken antibiotics or used vaginal health products within the last month (you may be able to re-enroll one month after stopping)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Pengming Sun, Fujian Maternal and Child Health Hospital

Phone: +86-591-87558732

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Fujian Maternity and Child Health Hospital
Registry
ClinicalTrials.gov
Start date
1 June 2022
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Cervical histopathology testing at baseline; Cervical histopathology testing at 6-month follow-up; Cervical histopathology testing at 12-month follow-up; Human Papillomavirus (HPV) viral integration test at baseline; Human Papillomavirus (HPV) viral integration test at 6-month follow-up; Human Papillomavirus (HPV) viral integration test at 12-month follow-up; Cervical cytology testing at baseline; Cervical cytology testing at 3-month follow-up; Cervical cytology testing at 6-month follow-up; Cervical cytology testing at 9-month follow-up; Cervical cytology testing at 12-month follow-up; 16SrRN...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov